While there are currently only a limited number of trials specifically targeting PTs, one notable clinical trial (NCT05998837) is examining alterations in urinary PT epithelial cells in CKD patients, both with and without diabetes, who are being treated with dapagliflozin compared with placebo. This evidence concerns the gene PTS and chronic kidney disease.